CD274 and non-small cell lung carcinoma: In addition, RNA sequencing analysis of PD-L1 inhibitor-resistant NSCLC patients revealed the presence of a PD-L1 variant fragment (v242 and v229, which retain the PD-1–binding domain) in vivo and confirmed its inhibitory effect on T-cell activity (46).